Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - Reporting Segment [Member] - USD ($) |
3 Months Ended | |||||
|---|---|---|---|---|---|---|
Mar. 31, 2025 |
Mar. 31, 2024 |
|||||
| Schedule of Reconciliation to the Consolidated Net Loss [Line Items] | ||||||
| General and administrative | [1] | $ 1,696,425 | $ 1,897,719 | |||
| Pre-clinical research | [1] | 61,993 | 430,384 | |||
| CMC | [1] | 224,597 | 377,820 | |||
| Clinical development | [1] | 1,434,804 | 826,117 | |||
| Depreciation and amortization | 161,708 | 162,257 | ||||
| Share based compensation expense | 98,558 | 346,477 | ||||
| Other segment items | [2] | 2,094 | ||||
| Total operating and segment expenses | 3,680,179 | 4,040,774 | ||||
| Reconciliation of net loss | ||||||
| Change in fair value of warrant liabilities | 76,867 | 26,716 | ||||
| Realized foreign currency translation loss from dissolution of subsidiaries | (7,171) | |||||
| Interest and dividends, net | 47,245 | 153,218 | ||||
| Segment and consolidated net loss | $ 3,563,238 | $ 3,860,840 | ||||
| ||||||
| X | ||||||||||
- Definition The amount of cmc. No definition available.
|
| X | ||||||||||
- Definition Amount of clinical development. No definition available.
|
| X | ||||||||||
- Definition The amount of pre-clinical research. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of operating and segment expenses. No definition available.
|
| X | ||||||||||
- Definition Amount, after tax, of expense for award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|